<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02278471</url>
  </required_header>
  <id_info>
    <org_study_id>141583</org_study_id>
    <nct_id>NCT02278471</nct_id>
  </id_info>
  <brief_title>The SCCS Polypill Pilot Trial</brief_title>
  <official_title>The SCCS Polypill Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators will examine the effect of the polypill on medication
      adherence, systolic blood pressure, and LDL cholesterol over a 12 month span.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess if a polypill-based approach to primary CVD prevention
      is feasible in a low socioeconomic status population. The study will assess whether a
      polypill approach is associated with better cardiovascular risk factor control compared with
      usual care.

      The polypill will be supplied as a compounded pill containing atorvastatin 10 mg, amlodipine
      2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg. The medications in the polypill have
      been extensively evaluated individually and in combination. Each of the medications in the
      polypill is approved by the United States Food and Drug Administration (FDA) and widely
      administered in the US for the treatment of and prevention of cardiovascular disease. The
      doses of each component medication included in the polypill are low, which should minimize
      the chance of any potential side-effects.

      In this study we assess medication adherence, systolic blood pressure, and LDL cholesterol
      over a 12 month span, in subjects taking the polypill versus subjects under usual care.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">June 27, 2018</completion_date>
  <primary_completion_date type="Actual">June 27, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>12 months</time_frame>
    <description>polypill versus usual care</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medication Adherence-Percentage of Pills Taken</measure>
    <time_frame>12 months</time_frame>
    <description>polypill arm-evaluation via pill counts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LDL Cholesterol</measure>
    <time_frame>12 months</time_frame>
    <description>Polypill versus usual care</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>2 months</time_frame>
    <description>polypill versus usual care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Adherence</measure>
    <time_frame>2 months</time_frame>
    <description>polypill-percentage of pills taken, evaluated via pill counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug Metabolite Profile</measure>
    <time_frame>12 months</time_frame>
    <description>LC/MS/MS-based drug metabolite profile assay screen in the polypill arm.
Note: Due to budgetary constraints, we did not immediately perform measurement of the secondary biomarker endpoints at the conclusion of the trial. We have secured alternate funding to perform biomarker measurements (glycemic markers, inflammatory profiles, and drug metabolites), which will be conducted in the next year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL Cholesterol</measure>
    <time_frame>2 months</time_frame>
    <description>polypill versus usual care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Resistance</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Measurement of HOMA-IR using fasting glucose and insulin.
Note: Due to budgetary constraints, we did not immediately perform measurement of the secondary biomarker endpoints at the conclusion of the trial. We have secured alternate funding to perform biomarker measurements (glycemic markers, inflammatory profiles, and drug metabolites), which will be conducted in the next year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Profile</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Plasma levels of IL-17, IFN-g, IL-6, IL-10, high sensitivity C-reactive protein, TNFa, IL-4.
Note: Due to budgetary constraints, we did not immediately perform measurement of the secondary biomarker endpoints at the conclusion of the trial. We have secured alternate funding to perform biomarker measurements (glycemic markers, inflammatory profiles, and drug metabolites), which will be conducted in the next year.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">303</enrollment>
  <condition>Hypertension</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects in this arm will not receive any investigational medications. They will remain on the same care that they are use to receiving.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polypill</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.
Polypill will be taken once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)</intervention_name>
    <arm_group_label>Polypill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Enrolled at the SCCS site in Mobile, Alabama, obtain care at Franklin Primary Health
             Center, or live in the surrounding area.

          -  Aged 45-75 years

          -  Baseline systolic blood pressure ≥120 mm Hg. In this open-label trial, the study
             physicians are permitted to prescribe any additional medication deemed appropriate to
             achieve blood pressure control.

        Exclusion Criteria:

          -  History of coronary heart disease or stroke

          -  History of cancer, except for basal cell skin cancer

          -  History of liver disease, not including chronic, clinically-stable hepatitis

          -  Laboratory evidence of hepatic dysfunction (an alanine aminotransferase level more
             than two times the upper limit of the normal range)

          -  Known renal disease, estimated creatinine clearance &lt; 60

          -  Current use of more than 2 anti-hypertensive medications

          -  LDL cholesterol ≥190 mg/dl

          -  Insulin-dependent diabetes

          -  Known intolerance to any of the components of the polypill

          -  Potassium &lt;3.4 or &gt;5.5 mEq/L

          -  Use of medications that interact with statins, including those affecting the
             cytochrome P450 system

          -  Current use of diuretics for indications other than hypertension

          -  Comorbidities that might be expected to limit lifespan during the 12-month follow-up
             period

          -  Inability to provide consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas J Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt Univeristy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Franklin Primary Health Center</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 13, 2014</study_first_submitted>
  <study_first_submitted_qc>October 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2014</study_first_posted>
  <results_first_submitted>June 25, 2019</results_first_submitted>
  <results_first_submitted_qc>September 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 1, 2019</results_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Thomas Wang</investigator_full_name>
    <investigator_title>Director of the Division of Cardiovascular Medicine</investigator_title>
  </responsible_party>
  <keyword>combination pill</keyword>
  <keyword>polypill</keyword>
  <keyword>primary prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 28, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT02278471/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Potentially eligible participants were invited to complete a baseline visit. During baseline visit, if eligibility confirmed, patients then randomized in open-label 1:1 fashion to either polypill arm or usual care arm. Only if baseline visit labs yielded an exclusionary result were participants then disqualified from further study participation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Usual Care</title>
          <description>Subjects in this arm will not receive any investigational medications. They will continue to receive usual medical care, as directed by their primary care providers.</description>
        </group>
        <group group_id="P2">
          <title>Polypill</title>
          <description>The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.
Polypill will be taken once daily.
Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="148"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Usual Care</title>
          <description>Subjects in this arm will not receive any investigational medications. They will continue to receive usual medical care, as directed by their primary care providers.</description>
        </group>
        <group group_id="B2">
          <title>Polypill</title>
          <description>The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.
Polypill will be taken once daily.
Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="155"/>
            <count group_id="B2" value="148"/>
            <count group_id="B3" value="303"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Mean age was the same for both the Polypill and the Usual care arms.</description>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="6"/>
                    <measurement group_id="B2" value="56" spread="6"/>
                    <measurement group_id="B3" value="56" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="164"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="141"/>
                    <measurement group_id="B3" value="292"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140" spread="17"/>
                    <measurement group_id="B2" value="140" spread="18"/>
                    <measurement group_id="B3" value="140" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LDL Cholesterol</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112" spread="37"/>
                    <measurement group_id="B2" value="114" spread="32"/>
                    <measurement group_id="B3" value="113" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Systolic Blood Pressure</title>
        <description>polypill versus usual care</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Subjects in this arm will not receive any investigational medications. They will continue to receive usual medical care, as directed by their primary care providers.</description>
          </group>
          <group group_id="O2">
            <title>Polypill</title>
            <description>The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.
Polypill will be taken once daily.
Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>polypill versus usual care</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138" spread="23"/>
                    <measurement group_id="O2" value="131" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Medication Adherence-Percentage of Pills Taken</title>
        <description>polypill arm-evaluation via pill counts.</description>
        <time_frame>12 months</time_frame>
        <population>adherence not assessed in usual care arm; incomplete data for 27 polypill participants, resulting in 101 analyzed of 128 polypill participants who completed 12 month visits</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Subjects in this arm will not receive any investigational medications. They will continue to receive usual medical care, as directed by their primary care providers.</description>
          </group>
          <group group_id="O2">
            <title>Polypill</title>
            <description>The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.
Polypill will be taken once daily.
Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)</description>
          </group>
        </group_list>
        <measure>
          <title>Medication Adherence-Percentage of Pills Taken</title>
          <description>polypill arm-evaluation via pill counts.</description>
          <population>adherence not assessed in usual care arm; incomplete data for 27 polypill participants, resulting in 101 analyzed of 128 polypill participants who completed 12 month visits</population>
          <units>percentage of pills taken</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="86" lower_limit="79" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>LDL Cholesterol</title>
        <description>Polypill versus usual care</description>
        <time_frame>12 months</time_frame>
        <population># of participants in polypill arm analyzed (126) does not match number of polypill participants completed (128; in the participant flow overview) because we were unable to obtain LDL values at baseline for 2 Polypill participants. The lab was unable to calculate and a reflex direct LDL was not processed.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Subjects in this arm will not receive any investigational medications. They will continue to receive usual medical care, as directed by their primary care providers.</description>
          </group>
          <group group_id="O2">
            <title>Polypill</title>
            <description>The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.
Polypill will be taken once daily.
Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)</description>
          </group>
        </group_list>
        <measure>
          <title>LDL Cholesterol</title>
          <description>Polypill versus usual care</description>
          <population># of participants in polypill arm analyzed (126) does not match number of polypill participants completed (128; in the participant flow overview) because we were unable to obtain LDL values at baseline for 2 Polypill participants. The lab was unable to calculate and a reflex direct LDL was not processed.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109" spread="32"/>
                    <measurement group_id="O2" value="98" spread="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure</title>
        <description>polypill versus usual care</description>
        <time_frame>2 months</time_frame>
        <population>The numbers of participants analyzed do not match those of the completed (in the participant flow overview) because this assessment was completed at baseline and 2 months; 291 patients (153 usual care, 138 Polypill) completed 2-month follow-up, whereas 275 (147 Usual Care, 128 Polypill) completed 12-month follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Subjects in this arm will not receive any investigational medications. They will continue to receive usual medical care, as directed by their primary care providers.</description>
          </group>
          <group group_id="O2">
            <title>Polypill</title>
            <description>The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.
Polypill will be taken once daily.
Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>polypill versus usual care</description>
          <population>The numbers of participants analyzed do not match those of the completed (in the participant flow overview) because this assessment was completed at baseline and 2 months; 291 patients (153 usual care, 138 Polypill) completed 2-month follow-up, whereas 275 (147 Usual Care, 128 Polypill) completed 12-month follow-up.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133" spread="19"/>
                    <measurement group_id="O2" value="128" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medication Adherence</title>
        <description>polypill-percentage of pills taken, evaluated via pill counts</description>
        <time_frame>2 months</time_frame>
        <population>adherence not assessed in usual care arm; incomplete data for 32 polypill participants, resulting in 106 analyzed of 138 polypill participants who completed 2 month visits</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Subjects in this arm will not receive any investigational medications. They will continue to receive usual medical care, as directed by their primary care providers.</description>
          </group>
          <group group_id="O2">
            <title>Polypill</title>
            <description>The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.
Polypill will be taken once daily.
Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)</description>
          </group>
        </group_list>
        <measure>
          <title>Medication Adherence</title>
          <description>polypill-percentage of pills taken, evaluated via pill counts</description>
          <population>adherence not assessed in usual care arm; incomplete data for 32 polypill participants, resulting in 106 analyzed of 138 polypill participants who completed 2 month visits</population>
          <units>percentage of pills taken</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="98" lower_limit="91" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drug Metabolite Profile</title>
        <description>LC/MS/MS-based drug metabolite profile assay screen in the polypill arm.
Note: Due to budgetary constraints, we did not immediately perform measurement of the secondary biomarker endpoints at the conclusion of the trial. We have secured alternate funding to perform biomarker measurements (glycemic markers, inflammatory profiles, and drug metabolites), which will be conducted in the next year.</description>
        <time_frame>12 months</time_frame>
        <posting_date>12/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDL Cholesterol</title>
        <description>polypill versus usual care</description>
        <time_frame>2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Subjects in this arm will not receive any investigational medications. They will continue to receive usual medical care, as directed by their primary care providers.</description>
          </group>
          <group group_id="O2">
            <title>Polypill</title>
            <description>The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.
Polypill will be taken once daily.
Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)</description>
          </group>
        </group_list>
        <measure>
          <title>LDL Cholesterol</title>
          <description>polypill versus usual care</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108" spread="35"/>
                    <measurement group_id="O2" value="90" spread="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Resistance</title>
        <description>Measurement of HOMA-IR using fasting glucose and insulin.
Note: Due to budgetary constraints, we did not immediately perform measurement of the secondary biomarker endpoints at the conclusion of the trial. We have secured alternate funding to perform biomarker measurements (glycemic markers, inflammatory profiles, and drug metabolites), which will be conducted in the next year.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <posting_date>12/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammatory Profile</title>
        <description>Plasma levels of IL-17, IFN-g, IL-6, IL-10, high sensitivity C-reactive protein, TNFa, IL-4.
Note: Due to budgetary constraints, we did not immediately perform measurement of the secondary biomarker endpoints at the conclusion of the trial. We have secured alternate funding to perform biomarker measurements (glycemic markers, inflammatory profiles, and drug metabolites), which will be conducted in the next year.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <posting_date>12/2020</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For the duration of the study period (Dec 2015 through June 2018) and for each participant's 12-month period of participation</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Usual Care</title>
          <description>Subjects in this arm will not receive any investigational medications. They will continue to receive usual medical care, as directed by their primary care providers.</description>
        </group>
        <group group_id="E2">
          <title>Polypill</title>
          <description>The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.
Polypill will be taken once daily.
Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary Artery Bypass Surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>non-CV death</sub_title>
                <description>alcohol toxicity</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>non-CV death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>death from motor vehicle accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>stroke-related death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Thomas J Wang</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>6159361717</phone>
      <email>thomas.j.wang@vumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

